Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Life & the LawAbortion

CLI and SBA File Comment on HHS Mandate

Click here to download a PDF version: CLI-SBA HHS_Mandate_Comment_June2012

 

 

Today the Charlotte Lozier Institute (CLI), the education and research arm of Susan B. Anthony List (SBA), joined with SBA in filing a comment on the preventive services mandate included in the Affordable Care Act.  The comment calls on HHS to rescind or amend the rule to exclude all conscientious objectors from its provisions requiring employers to make abortion-inducing drugs available to their employees at no cost.

 

Discussion of this issue to date has understandably been dominated by religious liberty concerns, but groups like CLI and SBA base their ethic of life on principles accessible to people of all faiths or no faith at all.  Pro-life groups, whether religious or not, are threatened across the board by the Obama Administration’s unprecedented mandate.

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

A person in a white shirt dropping an abortion ballot into a white box against a yellow background.

Abortion on the Ballot in November

October 2, 2026

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image